SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

Spectrum Pharmaceutecals, Inc. (SPPI)

SPPI RSS Feed
Add SPPI Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 12/9/2016 8:21:46 AM - Followers: 75 - Board type: Free - Posts Today: 0

http://www.spectrumpharm.com/

http://finance.yahoo.com/q/ks?s=SPPI+Key+Statistics

Company Presentation

http://www.sppirx.com/704-corporate-presentation.html

Spectrum Development Pipeline/Portfolio

Fusilev® (Levoleucovorin) for injection FDA Approved on April 29, 2011 for Use in Patients with Advanced Metastatic Colorectal Cancer and FDA Approved on March 7, 2008 for High-Dose Methotrexate Rescue Therapy in Osteosarcoma.
Zevalin® (ibritumomab tiuxetan), an FDA-Approved, Proprietary, Biological Drug for Indolent Non-Hodgkin's Lymphoma.
Belinostat a novel HDAC inhibitor in late stage clinical development for Peripheral T-cell Lymphoma, and other Solid Tumors (including Carcinoma of Unknown Primary, etc.)
Apaziquone, one of our lead development candidates, is a synthetic bio-reductive prodrug that is being investigated in the treatment of non-invasive bladder cancer, and began two Phase 3 studies in 2007.Spectrum also has three drugs in the Phase 2 stage of development: Ozarelix, for the treatment of prostate cancer and Ortataxel, for the treatment of taxane-refractory tumors.
The Company has three drugs in the Phase 1 stage of development: SPI-1620, an adjunct to chemotherapy, Elsamitrucin, which will target advanced solid tumors and Lucanthone, a chemotherapy sensitizer in the treatment of recurrent, malignant brain tumors.
Other drugs in development include SPI-014, used in the treatment of hyperphosphotemia in end stage renal disease (ESRD), and SPI-205 for chemotherapy induced neuropathy.

Recent News (Zevalin):

http://investor.spectrumpharm.com/releasedetail.cfm?ReleaseID=632354
http://investor.spectrumpharm.com/releasedetail.cfm?ReleaseID=632346

.  

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SPPI
Current Price
Volume:
Bid Ask Day's Range
SureTrader
SPPI News: Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World C... 12/08/2016 07:00:00 AM
SPPI News: Statement of Changes in Beneficial Ownership (4) 12/06/2016 06:25:07 PM
SPPI News: Spectrum Pharmaceuticals Highlights Survival Advantage in a Case Match Control Analysis of the PROPEL Study with FOLOTYN® (p... 12/06/2016 07:00:00 AM
SPPI News: Spectrum Pharmaceuticals Highlights Five Abstracts on ROLONTIS™ (eflapegrastim) & Poziotinib at the San Antonio Breast Canc... 12/05/2016 07:00:00 AM
SPPI News: Spectrum Pharmaceuticals Highlights Four Abstracts at the 58th Annual Meeting of the American Society of Hematology (ASH) in ... 12/02/2016 07:00:00 AM
PostSubject
#1575   Of interest, ASH abstract LBA-1 Comparison of Autologous antihama 12/09/16 08:21:46 AM
#1574   Reissued the poziotinib pre-clinical PR w some differenced antihama 12/08/16 01:58:51 PM
#1573   Here's the Zevalin abstract NOT highlighted by Spectrum antihama 12/07/16 10:05:19 PM
#1572   Here's the Zevalin abstract highlighted by Spectrum. I antihama 12/07/16 10:02:54 PM
#1571   For me the big enchilada in the room antihama 12/07/16 08:41:03 PM
#1570   Senate Clears Bill to Ease FDA Drug and antihama 12/07/16 04:30:08 PM
#1569   Here's the actual abstract 4149 Case Match Control antihama 12/07/16 09:20:54 AM
#1568   ASH abstract 4149 Case Match Control Analysis of antihama 12/07/16 09:09:39 AM
#1567   In March, EVOMELA Received FDA Approval for Two antihama 12/06/16 04:19:24 PM
#1566   Here’s the results from the abstract presented this antihama 12/06/16 12:39:34 PM
#1565   Including yourself, I think that makes two. I antihama 12/05/16 07:58:02 PM
#1564   anti I just want you to know that I Gator_Rasler 12/05/16 11:14:47 AM
#1563   CASI PR on Evomela antihama 12/05/16 10:05:38 AM
#1562   Some thoughts on SABCS 2016 PR antihama 12/05/16 09:51:22 AM
#1561   SABCS 2016 PR antihama 12/05/16 09:04:11 AM
#1560   The Pralatrexate - Romidepsin Doublet: A Well Tolerated antihama 12/02/16 08:28:50 AM
#1559   Spectrum Pharmaceuticals Highlights Four Abstracts at the 58th antihama 12/02/16 08:14:41 AM
#1558   P2 Immune Disorder HSCT Protocol NCT01821781 antihama 11/29/16 03:36:52 PM
#1557   Pretty detailed description of the trial in clinical antihama 11/29/16 02:59:45 PM
#1556   Another ASCT MS study using melphalan antihama 11/29/16 02:52:39 PM
#1555   Essentially the patient is getting 2 myleeoablative treatments antihama 11/29/16 02:40:16 PM
#1554   Zevalin Posting from Kyelion 6 days ago on Yahoo antihama 11/23/16 01:36:29 PM
#1553   No new bladder cancer tool in the shed, antihama 11/18/16 04:14:17 PM
#1552   BINGO!!! As I was suspecting the share price antihama 11/18/16 08:07:11 AM
#1551   Poziotinib PR issued today. While not the SABCS antihama 11/17/16 07:57:37 AM
#1550   Another 3% down today. While I think the antihama 11/16/16 05:11:25 PM
#1549   Based on what's happening to the stock price, antihama 11/15/16 02:00:50 PM
#1548   No Poziotimib data at SABCS 2016? At least antihama 11/15/16 07:45:34 AM
#1547   Re: Apaz antihama 11/10/16 07:53:08 PM
#1546   Ligand provided Evomela data. Was going through their antihama 11/10/16 05:38:58 PM
#1545   New FDA Guidance on “Non-Inferiority Clinical Trials to antihama 11/08/16 08:40:32 AM
#1544   And yet another Evomela study (NCT02909036) started in antihama 11/07/16 09:34:54 AM
#1543   Here's another Evomela P2 study (NCT01969435) sponserd by antihama 11/07/16 09:32:26 AM
#1542   Dr. Hari (Analyst Day presenter for Evomela) has antihama 11/06/16 10:20:58 PM
#1541   Presentations removed from SPPI.com! While I was antihama 11/05/16 09:04:12 AM
#1540   Mystery solved in where Seeking Alpha and others antihama 11/05/16 08:49:51 AM
#1539   if they had a CC, we could have antihama 11/04/16 09:44:00 AM
#1538   Holy Smolly, my prediction of 33.5M is off, antihama 11/03/16 10:49:31 PM
#1537   Sanofi and Regeneron were hit w a CRL antihama 10/28/16 11:19:37 PM
#1536   The ongoing apaziquone P3 trial has gone to antihama 10/25/16 07:51:09 PM
#1535   Prior to the last quarterly, doing a back antihama 10/22/16 08:55:25 PM
#1534   Article on the corporate board duties on the antihama 09/28/16 07:31:47 AM
#1533   Got this from Seeking Alpha antihama 09/24/16 10:10:16 PM
#1532   Some afterthoughts on my comments yesterday. antihama 09/20/16 11:50:37 AM
#1531   Seeking Alpha article article came out today antihama 09/19/16 08:46:11 PM
#1530   Not being a patent lawyer, I couldn't get antihama 09/19/16 01:49:33 PM
#1529   http://ir.navidea.com/phoenix.zhtml?c=68527&p=irol-newsArticle_print&ID=2203277 XJINVESTOR 09/16/16 08:23:20 AM
#1528   I can live with that assessment. But they XJINVESTOR 09/14/16 07:54:58 PM
#1527   Well, if their patent(s) is close to expiring antihama 09/14/16 06:30:42 PM
#1526   14-0 is a pretty good knock out punch. XJINVESTOR 09/14/16 04:46:49 PM
PostSubject